Syntimmune

16 articles about Syntimmune

• Alexion Completes Acquisition of Syntimmune

  11/2/2018

  Acquisition adds clinical-stage anti-FcRn antibody SYNT001 to company’s growing pipeline

• Alexion to Acquire Syntimmune

  9/26/2018

  Brings in clinical-stage anti-FcRn antibody SYNT001 with potential to address a number of rare IgG-mediated diseases

• 

  Alexion to Obtain Syntimmune for $400M up Front

  9/26/2018

  Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Syntimmune have just today announced that Alexion will be acquiring Syntimmune, a company working to produce antibody therapeutics that focus on the neonatal Fc receptor (FcRn).

• Syntimmune Announces FDA Orphan Drug Designation for SYNT001 in Treatment of Pemphigus

  9/12/2018

  Syntimmune, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SYNT001.

• 

  Biotech Movers and Shakers for July 16

  7/16/2018

  With the Independence Day holiday in the rearview mirror, numerous biopharma companies continued to adjust their leadership ranks and strengthen the members of various boards representing and overseeing the companies.

• Syntimmune Strengthens Leadership Team with Appointment of Chief Medical Officer

  7/9/2018

  Dr. Mario Saltarelli brings 25 years of experience from Vertex, Annexon, Shire, AbbVie and Pfizer

• Syntimmune to Present at Jefferies 2018 Global Healthcare Conference

  6/4/2018

  Syntimmune, Inc. announced that President and Chief Executive Officer Jean-Paul Kress, M.D., will present at the Jefferies 2018 Global Healthcare Conference.

• Syntimmune Announces Positive Preliminary Results from Clinical Proof-of-Concept Trial of SYNT001 in Pemphigus Vulgaris and Foliaceus

  5/17/2018

  Favorable safety and tolerability profile consistent with Phase 1a data SYNT001 treatment resulted in clinical improvement as measured by Pemphigus Disease Area Index (PDAI) score, with clinical effect persisting beyond the treatment period Rapid reductions in total IgG and circulating immune complex (CIC) levels

• Syntimmune Appoints Andrew Cheng, M.D., Ph.D., to Board of Directors, Bolstering Clinical Development Expertise

  4/25/2018

  Syntimmune, Inc. is a clinical-stage biotechnology company developing antibody therapeutics targeting FcRn

• 

  NYC Startup Syntimmune Names Former Biogen Exec as New CEO

  1/3/2018

  Syntimmune has appointed Jean-Paul Kress as president and CEO.

• Syntimmune Announces Clinical Data from First-in-Human Trial of Lead Candidate SYNT001

  11/2/2017

  An abstract of the Phase Ia trial results was posted today on the ASH website in advance of a poster presentation of the data, which will take place during the 59th ASH Annual Meeting, to be held in Atlanta, December 9-12.

• Tiny New York Biotech With Ties To Massachusetts, Syntimmune, Gets A $50 Million Boost

  6/21/2017

• Syntimmune Closes $50 Million Series B Financing Led By Apple Tree Partners

  6/21/2017

• Syntimmune Announces Breakthrough Results Of FcRn Inhibition Published In PNAS

  3/21/2017

• Virtual Biotech Syntimmune Taps Boehringer Ingelheim-Pfizer Alum as New CEO and Rakes in Some More Cash to Bring Drugs Into Clinic

  11/17/2016

• New York Startup Syntimmune Secures Second Tranche of $26 Million Series A, Will Use to Advance Autoimmune Therapy

  3/22/2016